Comparing Liposomal and Plain Bupivacaine for Pain Control After Minimally Invasive Thoracic Surgery

What this Trial Is About

Researchers are evaluating the pharmacokinetics of liposomal bupivacaine Exparel compared with plain bupivacaine after multilevel intercostal injections during minimally invasive thoracic surgeries. The study aims to assess plasma levels of bupivacaine after injections to ensure safety by remaining below toxic thresholds and to see if liposomal bupivacaine reduces opioid use and pain up to three months post-surgery. Secondary outcomes include rates of pneumonia, atrial fibrillation, and hospital stay length, which may be influenced by postoperative pain and inflammation. Participants receive either intercostal injections of 266 mg liposomal bupivacaine diluted to 30 ml or intercostal injections of 0.5% plain bupivacaine at 2 mgkg dose diluted to 30 ml. Injections target several intercostal spaces corresponding to surgical sites and adjacent levels. The study compares the plasma concentration profiles of both drugs after administration to evaluate safety and pharmacokinetics. During the study, researchers measure plasma bupivacaine levels at multiple time points from 0.5 to 72 hours after surgery. Participants are monitored for opioid consumption, pain levels, and complications such as pneumonia and atrial fibrillation. The study collects safety and outcome data throughout the postoperative period to understand both acute and chronic pain management effects, with the trial expected to complete by December 2026.

Liposomal Bupivacaine Versus Plain Bupivacaine After Intercostal Injections For Pain Management After Thoracoscopy